Deep response in multiple myeloma: a critical review.
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Novel and more effective treatment strategies against multiple myeloma (MM) have significantly prolonged patients’ survival and raised interest in the depth of response and its association with clinical outcome. Minimal residual disease (MRD) has emerged as one of the most relevant prognostic factors in MM and should be included in a new definition of complete response (CR). Although further standardization is still required, MRD monitoring should be applied in prospective clinical trials as a sensitive tool to compare and evaluate the efficacy of different treatment strategies, particularly in the consolidation and maintenance settings, and implement individualized therapy-monitoring approaches. Here, we review current definition of deep response in MM, advantages and limitations of current MRD assessment assays, clinical evidences for MRD monitoring as a prognostic tool for therapeutic decisions in MM, and challenges to develop uniform criteria for MRD monitoring.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632 · cited 1×
“The International Myeloma Working Group (IMWG) in 2006 has introduced normalization of sFLCs and absence of clonal PCs in BM biopsies by immunohistochemistry and/or immunofluorescence as additional requirements to define more stringent CR criteria [10].”
MethodBladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Initial genome sequencing and analysis of multiple myeloma
Chapman, M. A., Lawrence, M. S., Keats, J. J., Cibulskis, K., Sougnez, C., Schinzel, A. C., Harview, C. L., Brunet, J.-P., Ahmann, G. J., Adli, M., et al. (2011) · Nature · doi:10.1038/nature09837 · Cited by 1,433
Rajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Self-citationClinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070389 · Cited by 921
The genetic architecture of multiple myeloma
Morgan, G. J., Walker, B. A., & Davies, F. E. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3257 · Cited by 913
Zamagni, E., Patriarca, F., Nanni, C., Zannetti, B., Englaro, E., Pezzi, A., Tacchetti, P., Buttignol, S., Perrone, G., Brioli, A., et al. (2011) · Blood · doi:10.1182/blood-2011-06-361386 · Cited by 531
Rosiñol, L., Oriol, A., Teruel, A. I., Hernández, D., López-Jiménez, J., de la Rubia, J., Granell, M., Besalduch, J., Palomera, L., González, Y., et al. (2012) · Blood · doi:10.1182/blood-2012-02-408922 · Cited by 486
Barlogie, B., Shaughnessy, J., Tricot, G., Jacobson, J., Zangari, M., Anaissie, E., Walker, R., & Crowley, J. (2004) · Blood · doi:10.1182/blood-2003-04-1045 · Cited by 464
Research works printed but not linked: 1
- Ludwig H. Slavka G. Hubl W. Usage of HLC-ratio, FLC-ratio, Ife, PBMC infiltration and isotype suppression at best response reveals isotype suppression as most powerful parameter for identification of multiple myeloma patients with long survival ASH Annual Meeting Abstracts 1817 120 21 p. 1817
Cited by
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560
Self-citationFlores-Montero, J., Sanoja-Flores, L., Paiva, B., Puig, N., García-Sánchez, O., Böttcher, S., van der Velden, V. H. J., Pérez-Morán, J.-J., Vidriales, M.-B., García-Sanz, R., et al. (2017) · Leukemia · doi:10.1038/leu.2017.29 · Cited by 676
Prognostic and predictive biomarker developments in multiple myeloma
Wallington-Beddoe, C. T., & Mynott, R. L. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01162-7 · Cited by 172
Oberle, A., Brandt, A. P., Voigtlaender, M., Thiele, B., Radloff, J., Schulenkorf, A., Alawi, M., Akyüz, N., März, M., Ford, C. T., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.161414 · Cited by 115
Avet‐Loiseau, H., Miguel, J. F. S., Casneuf, T., Iida, S., Lonial, S., Usmani, S. Z., Spencer, A. G., Moreau, P., Plesner, T., Weisel, K. C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01814 · Cited by 103
Jagannath, S., Lin, Y., Goldschmidt, H., Reece, D., Nooka, A., Senin, A., Rodriguez-Otero, P., Powles, R., Matsue, K., Shah, N., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00507-2 · Cited by 90
Romano, A., Palumbo, G. A., Parrinello, N. L., Conticello, C., Martello, M., & Terragna, C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00699 · Cited by 63
Foulk, B., Schaffer, M., Gross, S., Rao, C., Smirnov, D. A., Connelly, M. C., Chaturvedi, S., Reddy, M. P., Brittingham, G. P., Mata, M., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.15003 · Cited by 60
Martínez‐López, J., Wong, S. W. K., Shah, N. D., Bahri, N., Zhou, K., Sheng, Y., Huang, C., Martin, T. G., & Wolf, J. L. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002037 · Cited by 37
Oliva, S., Gambella, M., Gilestro, M., Muccio, V. E., Gay, F., Drandi, D., Ferrero, S., Passera, R., Pautasso, C., Bernardini, A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12641 · Cited by 38
Cancer therapy: Attempt cure or manage drug resistance?
Hansen, E., & Read, A. F. (2020) · Evolutionary Applications · doi:10.1111/eva.12994 · Cited by 37
Sidana, S., Tandon, N., Dispenzieri, A. A., Gertz, M. A., Buadi, F. K., Lacy, M. Q., Dingli, D., Fonder, A. L., Hayman, S. R., Hobbs, M., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0271-1 · Cited by 32
Du, J., Wei, R., Jiang, S., Jiang, H., Li, L., Qiang, W., He, H., Shi, L., Ma, Q., Yu, K., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26583 · Cited by 36
Santockyte, R., Puig, Ó., Zheng, N., Ouyang, Z., Titsch, C., Zhang, Y. J., Pillutla, R. C., & Zeng, J. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c03357 · Cited by 26
Chapman, J. R., & Thoren, K. L. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101142 · Cited by 25
LI, J., Chen, S., Hu, Y., & Cai, J. (2016) · Oncology Letters · doi:10.3892/ol.2016.4204 · Cited by 17
Grieve, S., Puvvada, N., Phinyomark, A., Russell, K., Murugesan, A., Zed, E., Hassan, A., Légaré, J., Kienesberger, P. C., Pulinilkunnil, T., et al. (2021) · Nanomedicine · doi:10.2217/nnm-2021-0076 · Cited by 15
Kaddoura, M., Binder, M., Dingli, D., Buadi, F. K., Lacy, M. Q., Gertz, M. A., Dispenzieri, A. A., Kapoor, P., Hwa, Y. L., Fonder, A. L., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26439 · Cited by 15
Ramasamy, K., Vij, R., Kuter, D. J., Cella, D. F., Durie, B. G. M., Abonour, R., Rifkin, R. M., Ailawadhi, S., Lee, H. C., Cowan, A. J., et al. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.12.002 · Cited by 14
Standardisation of minimal residual disease in multiple myeloma
Innao, V., Allegra, A., Russo, S., Gerace, D. G., Vaddinelli, D., Alonci, A., Allegra, A. G., & Musolino, C. (2017) · European Journal of Cancer Care · doi:10.1111/ecc.12732 · Cited by 15
Minimal residual disease in multiple myeloma: Benefits of flow cytometry
Galtseva, I. V., Davydova, Y. O., Михайлович, К. Н., Julhakyan, H. L., & Менделеева, Л. П. (2017) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12757 · Cited by 16
Ghai, A., Fettig, N., Fontana, F., DiPersio, J. F., Rettig, M. P., O’Neal, J., Achilefu, S., Shoghi, K. I., & Shokeen, M. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00840-4 · Cited by 12
Mainou, M., Madenidou, A., Liakos, A., Paschos, P., Karagiannis, T., Bekiari, E., Vlachaki, E., Wang, Z., Murad, M. H., Kumar, S. K., et al. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12868 · Cited by 13
Milara, E., Alonso, R., Masseing, L., Seiffert, A. P., Gómez‐Grande, A., Aguilera, E. J. G., Martínez‐López, J., & González, P. S. (2023) · Physical and Engineering Sciences in Medicine · doi:10.1007/s13246-023-01265-0 · Cited by 10
Ramasamy, K., Avet‐Loiseau, H., Blimark, C. H., Delforge, M., Gay, F., Manier, S., Martínez‐López, J., Mateos, M., Mohty, M., van de Donk, N. W. C. J., et al. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000942 · Cited by 8
Chen, P., Yuan, Q., Yang, H., Wen, X., You, P., Hou, D., Xie, J., Cheng, Y., & Huang, H. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.04.007 · Cited by 8
Weisel, K. C., Mateos, M., Gay, F., Delforge, M., Cook, G., Szabó, Z. R., Desgraz, R., DeCosta, L., & Moreau, P. (2020) · Leukemia · doi:10.1038/s41375-020-01049-5 · Cited by 8
Infections in Patients with Multiple Myeloma in the Era of Novel Agents and Stem Cell Therapies
Al-Jasser, A. M., & Al‐Anazi, K. A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.81683 · Cited by 5
MDR1 polymorphisms affect the outcome of Chinese multiple myeloma patients
Xiao, Z., Yin, G., Ni, Y., Qu, X., Wu, H., Lu, H., Qian, S., Chen, L., Li, J., Qiu, H., et al. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.142 · Cited by 6
Baker, D. L., Bimali, M., Carrillo, L. F., Sachedina, A., Alapat, D. V., Hoque, M. S., Kottarathara, M. J., Parikh, R., Erra, A., Mitma, A. A., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.278779 · Cited by 4
FLOW CYTOMETRY IN THE DIAGNOSIS AND MONITORING OF MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA
Galtseva, I. V., Davydova, Y. O., Михайлович, К. Н., Julakyan, U. L., & Менделеева, Л. П. (2017) · Oncohematology · doi:10.17650/1818-8346-2017-12-2-80-94 · Cited by 2
Introductory Chapter: Multiple Myeloma in the Era of Novel Therapeutics
Al‐Anazi, K. A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82174 · Cited by 1
The significance of prognostic profiling in the treatment of patients with multiple myeloma
Mitrović, M., Sretenović, A., & Bila, J. (2020) · Medicinski podmladak · doi:10.5937/mp71-28137 · Cited by 1
Missassi, G., Ikoma, M. R. V., Bortolucci, C. M., Conti-Spilari, J. E., Simioni, A. J., Souza, M. P., & Colturato, V. A. R. (2021) · Annals of Hematology & Oncology · doi:10.26420/annhematoloncol.2021.1357 · Cited by 1
Improving the Monitoring of Multiple Myeloma Patients Using Blood Based Markers of Disease
Campbell, L. (2022) · Radar (Oxford Brookes University) · doi:10.24384/wa0k-xn78 · Cited by 3
Defining Immune Cell Profiles and their Role in Predicting Therapeutic Response in Multiple Myeloma
Acharya, S. (2017) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Multiple myeloma immunophenotyping: method validation
Vergnolle, I., Rieu, J., Avet‐Loiseau, H., Corre, J., & Vergez, F. (2019) · Annales de biologie clinique · doi:10.1684/abc.2019.1426
Ghai, A., Fettig, N., Fontana, F., DiPersio, J. F., Rettig, M. P., O’Neal, J., Achilefu, S., Shoghi, K. I., & Shokeen, M. (2021) · Research Square · doi:10.21203/rs.3.rs-647260/v1
Ghai, A., Fettig, N., Fontana, F., DiPersio, J., Rettig, M. P., Neal, J. O., Achilefu, S., Shoghi, K. I., & Shokeen, M. (2021) · Figshare · doi:10.6084/m9.figshare.16703044
Bozkürk, M. B., Topçuoğlu, C., Güneş, A. K., Öztürk, A., Öztürk, H. B. A., Kalan, U., Yıldız, S., Acar, K., Özdemir, Ş., & GÜÇEL, F. (2026) · Bozok Tıp Dergisi · doi:10.16919/bozoktip.1805472
Metadata
- Authors
- Fulciniti, M., Munshi, N. C., & Martinez-Lopez, J.
- Affiliations
- Harvard University (US)
- Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
- Corresponding author
- Fulciniti, Mariateresa
- Venue
- BioMed Research International
- Publisher
- Hindawi Limited
- Published
- 2015
- Volume
- 2015
- Pages
- 1-7
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- PMC
- PMC4689894
- OpenAlex
- W2191437528
- Cited by
- 40
- References
- 54
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 2 · 2022: 2 · 2021: 11 · 2020: 6 · 2019: 4 · 2018: 1 · 2017: 10 · 2016: 2
- FWCI
- 0.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- BioMed Research International (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- multiple myeloma, minimal residual disease, deep response, complete response, MRD monitoring, prognostic factors, consolidation therapy, maintenance therapy, treatment response criteria
- MeSH terms
- Humans, Multiple Myeloma, Prognosis, Remission Induction, Treatment Outcome, Neoplasm, Residual
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.